Key Highlights
- Johnson & Johnson delivered Q1 adjusted earnings of $2.70 per share, surpassing the Street’s $2.68 projection, while revenue reached $24.1 billion versus the anticipated $23.6 billion.
- The pharmaceutical segment experienced an 11.2% annual increase to $15.4 billion, propelled by blockbuster treatments Darzalex ($4.0B) and Tremfya ($1.6B).
- Management elevated its 2026 full-year revenue forecast to $100.8 billion and boosted adjusted earnings per share outlook to $11.55.
- Newly approved psoriasis treatment Icotyde has potential to generate approximately $10 billion at peak sales, according to Truist Securities projections.
- Shares of JNJ have climbed 15% since January 2026, dramatically outperforming the S&P 500’s modest 0.6-1% advance.
Johnson & Johnson unveiled its first-quarter 2026 financial performance Tuesday morning, delivering numbers that exceeded Wall Street’s projections across key metrics.
Revenue for the quarter reached $24.1 billion, representing a 10% year-over-year increase and topping the analyst consensus of $23.6 billion gathered by FactSet. Adjusted profit per share registered at $2.70, narrowly surpassing the expected $2.68.
Shares responded positively, climbing approximately 1.2% during early morning trading hours.
These results arrive during a transformative period for the healthcare conglomerate. The organization has strategically pivoted away from consumer products in recent years — divesting the Kenvue business, currently subject to acquisition by Kimberly-Clark — to sharpen its focus on pharmaceutical innovation and medical technology.
The pharmaceutical business segment emerged as the standout performer, expanding 11.2% compared to the prior year to reach $15.4 billion. This figure exceeded FactSet’s projection of $15.2 billion.
Darzalex, the company’s leading multiple myeloma therapy, generated $4.0 billion during the three-month period, climbing from $3.2 billion in the corresponding quarter of 2025. Analysts had anticipated $3.9 billion.
Tremfya, an interleukin-23 inhibitor deployed against autoimmune disorders, recorded $1.6 billion in quarterly sales, surging from $956 million twelve months earlier and comfortably beating the $1.4 billion forecast.
Autoimmune Portfolio Expansion
Regulatory authorities granted approval for Tremfya’s subcutaneous formulation last September, authorizing its use in ulcerative colitis and Crohn’s disease patients, establishing it as the pioneering self-administered medication in its class. This convenience factor provides a competitive edge against AbbVie’s Skyrizi, which necessitates clinical administration for initial treatment.
Additionally, J&J secured FDA clearance last month for Icotyde, an innovative oral interleukin-23 inhibitor targeting plaque psoriasis, stemming from a 2017 partnership with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects the therapy could achieve approximately $10 billion in peak annual revenue. The company has yet to report commercial figures for this product.
The medical technology segment contributed $8.6 billion in quarterly sales, matching analyst projections.
Net profit totaled $5.2 billion, falling short of FactSet’s $6.5 billion estimate — marking the second straight quarter where bottom-line results disappointed expectations.
Updated Projections and Ongoing Litigation
Looking ahead to the complete fiscal year, management now anticipates revenue of $100.8 billion, an increase from the previous $100.5 billion target. The adjusted earnings per share guidance was similarly elevated to $11.55 from $11.03. The Street had been modeling $11.54 per share on sales of $100.6 billion.
Significant legal challenges continue to weigh on the organization. Concluding the fourth quarter of 2025, the company confronted 74,360 pending lawsuits alleging it deliberately marketed talcum powder products containing carcinogenic asbestos. A recent bankruptcy strategy involving subsidiary Red River Talc was rejected by a Texas court, permitting individual claims to advance.
The company continues to assert that its baby powder offering, now marketed under the Kenvue banner, contains no asbestos and remains safe for consumers.
Among the 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or similar recommendation. Two firms rate the stock as a Sell.
Year-to-date performance in 2026 shows JNJ advancing 15%, substantially outpacing the S&P 500’s gain of approximately 0.6% to 1% during the identical timeframe.
